secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0001104659-21-139169
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports NC318 37% DCR, 5.0 mo median PFS; NC410 safe in Ph1
--------------------------------------------------------------------

- NC318 Phase 1/2: 37% disease control rate, median PFS 5.0 mo across all tumors; lung cohort 45% DCR, median PFS 5.2 mo.
- Two NSCLC patients on NC318 >2 years: one CR at 2.8 years, one PR at 2.2 years.
- Modeling predicts 800 mg weekly NC318 yields ~10x exposure; sS15 may be biomarker for patient selection.
- NC410 Ph1 (n=19) up to 60 mg Q2W: no dose-limiting toxicities; shows target binding, immune modulation, ECM remodeling.
- Non-clinical data: NC410 synergizes with bintrafusp alpha (TGF-β trap) for tumor control in colon cancer model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465921139169/0001104659-21-139169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465921139169/tm2132890d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-139169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer